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ABSTRACT
Purpose: Exosomes derived from human mesenchymal stem cells (hMSCs) cultured under hypoxic
conditions contain proteins and growth factors that promote angiogenesis. This study investigated
the effect of intravitreal administration of these exosomes on retinal ischemia using a murine model.
Methods: Oxygen-induced retinopathy (OIR) was induced by exposing one-week-old male C57BL/6J mice
to 5 days of 75% hyperoxic conditioning, and returning to room air. After hyperoxic conditioning, the
right eye of each mouse was injected intravitreally with 1 µl saline or exosomes derived from hMSCs and
compared to control mice of the same age raised in room air without OIR injected intravitreally with
saline. Two weeks post-injection, fluorescein angiography (FA) and phase-variance optical coherence
tomography angiography (pvOCTA) were used to assess retinal perfusion. Retinal thickness was deter-
mined by OCT. The extent of retinal neovascularization was quantitated histologically by counting
vascular nuclei on the retinal surface.
Results: Among eyes with OIR, intravitreal exosome treatment partially preserved retinal vascular flow in
vivo and reduced associated retinal thinning; retinal thickness on OCT was 111.1 ± 7.4µm with saline
versus 132.1 ± 11.6µm with exosome, p < 0.001. Retinal neovascularization among OIR eyes was reduced
with exosome treatment when compared to saline-treated eyes (7.75 ± 3.68 versus 2.68 ± 1.35
neovascular nuclei per section, p < 0.0001). No immunogenicity or ocular/systemic adverse effect was
associated with intravitreal exosome treatment.
Conclusions: Intravitreal administration of exosomes derived from hMSCs was well tolerated without
immunosuppression and decreased the severity of retinal ischemia in this murine model. This appealing
novel non-cellular therapeutic approach warrants further exploration.
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Introduction
Bone marrow-derived mesenchymal stem cells (MSCs) have
tissue healing capabilities and are currently widely explored
for numerous therapeutic applications. It has been demon-
strated that the effects of MSCs are mediated mostly via
paracrine signaling factors to surrounding endogenous cells,
rather than direct cell replacement.1–4
Exosomes are small (50–150 nm) bi-lipid membrane intra-
cellular vesicles, which are packaged with and transport a
variety of proteins and RNAs from their cell of origin to
neighboring cells.5 Exosomes were recently characterized to
provide cell-to-cell communication that mediates complex
cellular processes, such as antigen cross-presentation, stem
cell differentiation and angiogenesis.6–9
Recent studies have demonstrated that exosomes derived
from MSCs have a protective effect in models of tissue ischemia
and reperfusion injury.9–16 For example, treatment with exo-
somes derived from MSCs significantly decreased myocardial
infarction size in murine models of myocardial ischemia-
reperfusion12,13 and significantly improved blood flow recovery
in hind limb ischemia models.9 A recent comprehensive proteo-
mic analysis of exosomes derived from human MSCs cultured
under hypoxic, serum-free conditions revealed that these exo-
somes express a diverse profile of factors involved in angiogen-
esis including signaling proteins associated with nuclear factor
kappa B (NFkB), platelet-derived growth factor (PDGF), epider-
mal growth factor (EGF) and fibroblast growth factor (FGF).17
Studies have determined that intravitreal injection of MSCs
in animal eyes with acute ischemia-reperfusion injury results
in preservation of the ganglion cell layer, an effect that could
be replicated by intravitreal injection of conditioned media.18
Since some safety issues have been noted using intravitreal
injection of MSCs in some animal models,19 this study inves-
tigated the effect of intravitreal administration of exosomes
derived from MSCs as a potential non-cellular therapy for
retinal ischemia.
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Methods
Animals
This study protocol was approved by the Institutional Animal
Care and Use Committee at the University of California Davis
before initiation. The study was conducted according to an
approved protocol and in accordance with AAALAC and with
the ARVO statement for the Use of Animals in Ophthalmic
and Vision Research.
Twelve C57BL/6J mice (Jackson Laboratories; strain 000664)
were used in this study. All mice were male and one week of
age at the initiation of the study. The mice were maintained
with their nursing mothers at the vivarium for the duration of
the study until 4 weeks of age. Mice were divided into three
groups (see Intravitreal Injections section below), and all mice
in all three groups were from the same litter.
Oxygen-induced retinopathy model
A well-established protocol for inducing oxygen-induced reti-
nopathy (OIR) in mice was used to induce retinal ischemia
simulating retinopathy of prematurity (ROP).20 At the age of
one week, eight mice were place in a closed chamber under an
oxygen concentration of 75% for 5 days. The chamber
remained closed during the 5-day hyperoxic exposure period.
The hyperoxic condition was monitored continuously using
an oxygen sensor (MiniOX I oxygen analyzer; MSA
Instrument Division, Pittsburgh, PA), which ensured an oxy-
gen concentration of 75.0%±2.0% for the entire duration.
Following the hyperoxic exposure, room air becomes rela-
tively hypoxic to the mice, and by 2 weeks, all eyes develop
retinal ischemia and neovascularization.20 An advantage of
this model is that the level of ischemia is quantifiable, based
on the count of neovascular cell nuclei on the vitreal surface
of the retina on histology20 (see Tissue Processing and
Histology section below for the full details). The remaining
four mice were kept at room air for the same 5-day period, as
a control group without OIR.
Exosome isolation
Fresh bone marrow from three young non-smoking males
was obtained from a commercial vendor (Lonza). MSCs
were isolated as previously described and used for exosome
isolation at passage 6.17 Exosomes were isolated from media
(OptiMEM) that had been conditioned by MSCs for 48 hours
under 1% oxygen tension (serum-free). The conditioned
media were precleared of cells and cellular debris via serial
centrifugation of the supernatants: a) 500 x g for 10 minutes,
b) 2000 x g for 15 minutes. Exosomes were concentrated and
washed from the resulting supernatants using tangential flow
filtration with a 300 kDa molecular weight cutoff polyether-
sulfone (PES) membrane (Pall, Port Washington, NY), using a
diafiltration wash step with 500 mL of sterile PBS. This step
allowed the elimination of cells, cell debris and microvesicles.
The resulting exosome concentrated solution was further con-
centrated using a VivaSpin filtration column with a 300 kDa
molecular weight cutoff PES membrane. The resulting
concentrated exosome solution was aliquoted at 10 µL and
kept at −80ºC until used. Vesicle concentration was measured
using DC assay (BioRad, Hercules, CA), and size distribution
was determined by NanoSight LM10HS (Malvern, Amesbury,
MA). This process has previously been described in detail.17
This isolation protocol highly enriched the isolates for pur-
ified exosomes suspended in a PBS buffer.
Intravitreal injections
Intravitreal injections were performed after the 5 days of hyper-
oxic exposure, when the mice were 12 days old. An intravitreal
injection was performed once in the right eye of each mouse. It
was performed using a pars planar and transconjunctival
approach under isoflurane (2–3% in oxygen) anesthesia. After
instilling a drop of 5% betadine solution into the fornix, a sterile
33g needle attached to a Hamilton syringe was used to deliver 1 µl
of isolated exosome solution or saline per eye. There were three
groups of mice (n = 4 in each group), which were injected as
follows: Group 1 included four mice that underwent the OIR
induction and were injected with 1 µl saline; Group 2 included
four mice that underwent the OIR induction and were injected
with exosomes derived from human MSCs (20 µg in 1 µl), and
Group 3 included four mice without OIR that were kept at room
air at all times and injected with 1 µl saline. Following intravitreal
injection, antibiotic eye ointment was applied to the injected eye.
Retinal imaging
Animals were imaged 2 weeks after intravitreal injection.
Prior to imaging, all eyes were examined by indirect ophthal-
moscopy to determine whether any ocular complications had
occurred following the intravitreal injection of exosomes, such
as intraocular inflammation, hemorrhage, cataract, retinal
detachment or endophthalmitis. A multimodal retinal ima-
ging system specifically designed and built for in vivo mouse
retinal imaging was used. This system integrates multichannel
scanning laser ophthalmoscopy (SLO) and optical coherence
tomography (OCT) and allows simultaneous collection of
complementary information from the tissue, greatly simplify-
ing data registration and analysis. This system has been
described in detail elsewhere.21 In this study, it was used to
perform simultaneous fluorescein angiography (FA) and
phase variance OCT angiography (pvOCTA). The pvOCTA
detects flow and perfusion in the retinal vasculature and does
not visualize non-perfused vessels.
Fluorescein sodium (0.1 ml of 1%) was injected into the tail
vein prior to anesthesia and imaging. The mouse retinal
imaging was performed under isoflurane (2–3% in oxygen)
inhalation anesthesia. A heating pad was used to maintain
normal body temperature, and avoid the development of
“cold cataracts” during imaging.22 The head was held rigidly
by a “bite-bar” that also served to keep its snout inside the
gaseous isoflurane anesthetic delivery tube.
With its customized scanning head, the scanning field of
view (FOV) can be up to 50 degrees, while software control
allows limiting the scanning to any square subfield of the larger
field. With a customized contact lens mounted to the scan head,
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the mouse cornea was kept hydrated and clear, greatly facilitat-
ing mouse handling during a single imaging session.
Retinal thickness was measured using OCT B-scan images,
which were taken at identical locations (horizontal scans
through the optic disc). Retinal thickness was measured as the
distance between the internal limiting membrane (ILM) and the
retinal pigment epithelium (RPE), between 800 points and 1mm
temporal from the optic disc margin on the OCT B-scan image.
The retinal thickness values were averaged, and the means were
compared using an unpaired two-tailed Student’s t-test.
Tissue processing and histology
Following imaging, the mice were euthanized by asphyxiation
with gaseous CO2 in a closed chamber, and the right eyes
were harvested promptly for histological analysis. The con-
tralateral eye (untreated left eye) from the exosome-treated
mice (Group 2) was harvested and fixed as well for analysis.
The eyes were enucleated, fixed in 4% paraformaldehyde,
and embedded in paraffin.23 For orientation in paraffin, the
superior region of each eye was marked using tissue dye (The
Davidson Marking System, Bradley Products Inc., Bloomington,
MN, catalog #1003–6). Sagittal sections were cut using a Leica
RM2125RT microtome (Leica, Nussloch, Germany) at 6
microns, placed on SuperFrost Plus microscope slides, and
dried overnight at room temperature. Based on the previous
orientation of each eye in the paraffin embedding step, a section
through the optic disk represented a sagittal section.
Sections underwent standard Hematoxylin-Eosin staining.
For each eye, eight sections were carefully viewed at 40X
magnification, and neovascular nuclei on the retinal surface
were counted. Sections used for counting included four retinal
sections from either side of the optic disc, at a distance of 30
to 90 microns from the optic disc, in accordance with the OIR
protocol.20 In each section, neovascular nuclei were identified
by their location on the vitreal side of the ILM on the retinal
surface. Therefore, a total of eight sections (four sections from
each side of the optic nerve) were counted from each eye. The
means for each study group were compared using an unpaired
two-tailed Student’s t-test. Statistical analysis was performed
using IBM SPSS Statistics version 21.0.
Slides were viewed and digitized images captured using a
Nikon Eclipse E800 and QCapture software (QImaging, Surrey,
Canada).
Proteomic data analysis
Proteomic data analysis was performed on data obtained from
the analysis of exosomes derived from human MSCs cultured
under hypoxic conditions as previously reported.17 This is a new
analysis of previously published data collected from exosomes
derived from hMSC as used in this study.17 Briefly, a multi-
layered analysis was employed that included clustered network
analysis using CytoScape (=) and Ingenuity Pathway Analysis
software (Qiagen, Redwood City, CA, USA). The Spike database
was used to detect proteins for which there was experimental
evidence for physical interactions (i.e., yeast-2-hybrid, co-
immunoprecipitation) and was accessed via CytoScape.
Results
Exosomes derived from human MSCs cultured under hypoxic
and serum-free conditions were injected intravitreally into
murine eyes with OIR to assess the protective effects of this
therapy on ischemic retina. Table 1 summarizes the experi-
mental design of the study arms. The eyes with OIR treated
with exosomes had three different sets of controls for com-
parison: 1) eyes without OIR injected with saline, 2) eyes with
OIR injected with saline, and 3) eyes with OIR without treat-
ment (contralateral eye of exosome-treated eye with OIR).
In vivo retinal imaging
To evaluate the extent of retinal ischemia and neovasculariza-
tion, the retinal perfusion of the mice was analyzed in vivo using
simultaneous combined FA and pvOCTA imaging of the retina
2 weeks following intravitreal injection of saline or exosomes.
All eyes of mice that underwent OIR induction protocol devel-
oped areas of retinal capillary non-perfusion and retinal neo-
vascularization that were apparent on FA and pvOCTA,
whereas eyes of mice grown under room air conditions (i.e.,
without OIR) had normal retinal vascular filling with no areas
of retinal non-perfusion or neovascularization (Figure 1). These
areas of retinal capillary non-perfusion and retinal neovascular-
ization on FA and pvOCTA were more pronounced in saline-
injected eyes with OIR when compared to OIR eyes treated with
intravitreal exosome (Figures 1C and F).
Figure 2 illustrates B-scan cross-sectional OCT images of
the retina with superimposed pvOCTA signals (red), showing
the location of vascular flow relative to the retinal layers. An
increased blood flow on the inner surface of the retina was
noted in all eyes with OIR in groups 1 and 2 indicative of
retinal neovascularization. Retinal thickness was measured
using the OCT B-scan images and was found to be 111.1 ±
7.4 µm in Group 1, 132.1 ± 11.6 µm in Group 2, and 205.9 ±
18.8 µm in Group 3. Eyes with OIR (Groups 1 and 2) had
significantly thinner retina in comparison with eyes without
OIR of mice that had been exposed only to room air (Group
3) (p < 0.001 for both). Among eyes with OIR, retinal thick-
ness in the eye treated with saline (Group 1) was thinner than
in the eye treated with exosomes (Group 2) (p < 0.001).
Histological analysis of retinal neovascularization
To quantitate the level of retinal ischemia, histologic analysis
was conducted. By counting the number of neovascular nuclei
on the retinal surface in eight sections per eye taken at similar
distances from the optic disc, a quantitative measure of the
Table 1. Summary of study groups.
Group OIR Eyes
Intravitreal
injection N
Tests performed at 2 weeks
following injection
1 Yes OD Saline 4 FA, pvOCTA, histology
2 Yes OD Exosomes 4 FA, pvOCTA, histology
2 Yes OS No 4 Histology only
3 No
(room air)
OD Saline 4 FA, pvOCTA, histology
(OIR = oxygen induced retinopathy; FA = fluorescein angiography; pvOCTA = phase
variance optical coherence tomography angiography; OD= right eye; OS = left eye).
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degree of retinal neovascularization was obtained for each
study eye. An example of retinal neovascularization on the
retinal surface, that is, the vitreal side of the ILM is presented
in Figure 3.
In Group 1, OIR eyes treated with saline, there was an
average of 7.75 ± 3.68 neovascular nuclei per section. In
Group 2, OIR eyes treated with exosomes, there was an
average of 2.68 ± 1.35 neovascular nuclei per section. In the
untreated fellow eyes of mice from Group 2, there was an
average of 7.0 ± 2.48 neovascular nuclei per section. In eyes
without OIR (Group 3), there was an average of 0.12 ± 0.33
neovascular nuclei per section. All eyes from mice exposed
to OIR induction had significantly higher neovascular
nuclei counts than Group 3 eyes without OIR (p < 0.0001
for all). There was no difference between Group 1 eyes
(OIR eyes treated with saline) and the untreated fellow
eyes of mice from Group 2 (untreated OIR eyes) (p =
0.35). In Group 2 eyes treated with exosomes, the neovas-
cular nuclei counts were significantly lower than saline
treated Group 1 eyes with OIR and the untreated fellow
eyes with OIR in Group 2 (p < 0.0001 for both). These
results are presented graphically in Figure 3D. We also note
that no signs of ocular inflammation were noted on exam-
ination and histological analysis of the eyes injected with
exosomes.
hMSCs-derived exosome proteomic analysis
To assess factors contained within exosomes derived from
human bone marrow-derived MSCs that mediate their
protective affects, we further analyzed data obtained previously
using a novel, unbiased proteomics method, high-resolution
isoelectric focusing liquid chromatography couple tandem mass
spectrometry (HiRIEF LC-MS/MS). This new analysis was per-
formed on previously published data collected from exosomes
derived from hMSC as used in this study.17 A total of 1927
proteins were identified in each exosome sample generated from
MSCs derived from three different human donors (see Table S1,
Supplemental Digital Content 1.We previously reported that the
exosomes expressed 92 of the top 100 most identified exosomal
marker proteins from the ExoCarta database in our exosome
samples (see Table S2, Supplemental Digital Content 2, and
Figure S1, Supplemental Digital Content 3). We also previously
reported the vascular-protective proteins identified in MSC
exosomes.17
Here, we present new analysis of the proteomic data
demonstrating that exosomes derived from human MSCs
are packaged with numerous pro-survival-associated pro-
teins from the cAMP response element-binding protein
(CREB) pathway using Ingenuity Pathway Analysis
(Qiagen) (Figure 4). Clustered network analysis of pro-
tein–protein interaction networks (CytoScape, Spike data-
base) determined clustering of proteins associated with
pro-survival heat shock protein (HSP) pathways:
HSPA1A, HSPA4, HSPA5, HSPA8, HSPA9, HSP90AA1,
HSPB90, HSPBP1, HSPD1, HSPG2, HSPH1 (Figure 5).
These data collectively demonstrate that exosomes derived
from human MSCs contain numerous proteins associated
with pro-survival signaling cascades. The delivery of such
prosurvival proteins to retinal tissues serves as an
Figure 1. In vivo retinal vascular flow imaging of eyes with and without oxygen induced retinopathy (OIR) demonstrating protective effect of intravitreal exosome
treatment on retinal ischemia. (A-C) Fluorescein angiogram. Normal retinal perfusion is demonstrated in the eye without OIR (A). In the eyes with OIR, areas of retinal
ischemia and neovascularization are seen which are more pronounced in the eye that was treated with intravitreal saline (B) when compared to OIR eyes treated with
intravitreal exosomes (C). (D-F) Corresponding phase variance OCT angiography maps of the retinal vascular flow of the same eyes as shown in A (D), B (E) and C (F).
Normal retinal capillary perfusion is demonstrated in the eye without OIR (D). The eyes with OIR show marked retinal capillary non-perfusion which is more
pronounced in the eye that was treated with intravitreal saline (E) when compared to the eye treated with intravitreal exosomes (F). The horizontal lines are motion
artifacts. The length of the horizontal bar scale at the lower left corner of each image represents 0.17 mm.
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additional potential mechanism by which MSC exosomes
may mediate their protective effects in the OIR model of
retinopathy.
Discussion
In this study, we used a murine model of OIR to study the
effect of intravitreal administration of exosomes derived from
human bone marrow MSCs on retinal ischemia. This model
was used as it is a well-established, validated and quantifiable
model for retinal ischemia.20,24 We used a novel three-dimen-
sional in vivo retinal imaging system specifically designed for
murine eyes, that is, pvOCTA, as well as the traditional FA to
evaluate retinal perfusion in vivo. Furthermore, histologic
analysis was used to evaluate the effect of intravitreal admin-
istration of exosomes from human bone marrow MSCs in this
model of retinal ischemia.
Both in vivo retinal imaging techniques, pvOCTA and FA,
demonstrated that the degree of retinal ischemia and the
development of retinal neovascularization in eyes exposed to
the OIR induction were reduced in eyes treated with intravi-
treal exosomes (Group 2) compared to saline treated controls
(Group 1) (Figure 1). The newer pvOCTA allows higher
resolution three-dimensional imaging of the retinal
Figure 2. Composite OCT and phase-variance OCT angiography B-scan images of study eyes showing differences in retinal thickness in the three study groups. The
retina is notably thicker in the eye without OIR (A) when compared to the eye with OIR treated with saline (B) or exosomes (C). Red indicates vascular flow, and retinal
neovascularization is demonstrated by red on the retinal surface in eyes with OIR (B,C) (hollow arrows). The length of the vertical and horizontal arm of the L-shaped
scale at the lower left corner of each image represents 100 µm.(D) Mean ± SD of retinal thickness measurements in each study group. Both OIR groups (Groups 1 and 2)
had significantly reduced retinal thickness compared with the control group (Group 3); the retinal thickness was significantly reduced in saline-treated eyes (Group 1) in
comparison with exosome-treated eyes (Group 2) (p < 0.001 for all).
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Figure 3. Histologic retinal section with Hematoxylin-Eosin staining demonstrating retinal neovascularization on the retinal surface. (A) A cross section of the retina
from an eye without OIR shows no neovascular nuclei on the retinal surface. (B) A cross section of the retina from an eye with OIR treated with saline showing several
foci of retinal neovascularizations extending to the vitreal side of the ILM (hollow arrows), as well as some red blood cells in the vitreous indicating associated
vitreous hemorrhage. (C). A cross section of the retina from an eye with OIR treated with exosomes showing an area of retinal neovascularization (hollow arrow).
There were significantly less neovascular nuclei on the vitreal side of the ILM in these eyes compared to control OIR eyes treated with saline. [ILM = internal limiting
membrane; VH = vitreous hemorrhage). The separation of the retina from the RPE is an artifact of fixation. (D). Comparison of mean±SD neovascular nuclei counts of
the eyes included in the study. The values represent means obtained from four eyes per group with eight sections per eye. Eyes treated with exosomes (group 2) had
significantly lower neovascular nuclei counts than eyes treated with saline (Group 1), as well as their fellow untreated eyes (P < 0.001 for both, indicated by a red
star).
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Figure 4. Ingenuity Pathway Analysis demonstrated exosomes derived from hMSCs are packaged with CREB signaling proteins that have been shown to mediate
survival of neurons and other cell types. Colored nodes indicate detection in the exosomes, white nodes indicates not detected.
Figure 5. Clustered network analysis of protein–protein interaction networks using CytoScape and the Spike database demonstrated presence of HSP associated
pathway proteins. Red nodes = detected in exosomes, blue nodes = not detected in exosomes. Edges indicate protein-protein interactions as demonstrated by
experimental evidence (e.g., co-immunoprecipitation, yeast 2-hybrid).
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vasculature.25 The change in retinal perfusion was appreciated
at all levels of the retinal vasculature using pvOCTA. The
degree of retinal thinning associated with the induced retinal
ischemia in eyes with OIR was less pronounced in eyes treated
with exosomes (Group 2) when compared to saline treated
controls (Group 1) (132.1 ± 11.6 µm vs. 111.1 ± 7.4 µm,
respectively, p < 0.001). These results indicate that although
intravitreal injection of exosomes from human MSCs did not
completely prevent retinal ischemia and neovascularization in
the OIR model, the treatment significantly attenuated the
severity of OIR both qualitatively and quantitatively.
The histologic analysis of eyes in this study further sup-
ports the in vivo retinal imaging findings that intravitreal
injection of exosomes from human MSCs significantly
reduced the degree of retinal ischemia and neovascularization
associated with OIR. While eyes with OIR treated with saline
(Group 1) had similar mean neovascular nuclei counts per eye
as the fellow untreated eyes with OIR, eyes with OIR treated
with exosomes (Group 2) has significantly lower mean neo-
vascular nuclei counts. This is consistent with the observed
reduced level of retinal neovascularization visualized using in
vivo retinal vascular imaging in these mice. Another impor-
tant point is that eyes treated with exosomes showed no signs
of ocular inflammation on examination and histological
analysis.
Murine model of OIR is a well-established preclinical model
for quantitating retinal ischemia and neovascularization.20
However, it is important to point out that some variability in
the development of OIR has been reported even among mice of
the same strain. In our study, the OIR was induced in the same
strain of mice from the same vendor at the same time to
minimize any variability between study groups. The number
of mice per group was limited by the size of the hyperoxic
chamber and litter. The time course of development of retinal
neovascularization is reported to peak at postnatal day 17 to 21
(i.e., 1 week after hyperoxic conditioning) with evidence of
tissue repair thereafter.20 Due to logistical issues, our study
evaluated mice on postnatal day 26 which may have attenuated
the retinal vascular changes associated with OIR. Although this
time point may not have been ideal, a statistically significant
difference in retina neovascularization was noted between the
study groups. The potential advantage of waiting a few days
longer till day 26 to compare study groups is that the neuro-
protective effects of exosome treatment on retinal thickness
may be appreciated more readily.
The effect of exosomes on their target tissues is variable
because exosomes secreted from different cell types or under
different conditions may vary in their content. Exosomes
derived from retinal astroglial cells suppress choroidal neo-
vascularization, while exosomes from retinal pigment epithe-
lial cells have shown pro-angiogenic effects when
administered intravenously and via periocular injections.26,27
With RPE cells, oxidative stress can cause the cells to increase
exosome secretion. These exosomes from RPE cells contain
higher concentrations of pro-angiogenic signaling proteins in
response to oxidative stress.27,28 Similarly, in our study,
hypoxic stress was used to increase exosome production of
angiogenic and pro-cell survival factors in cultured MSCs
from human bone marrow.17,29
The pro-angiogenic profile of the exosomes derived from
human MSCs under hypoxic conditions has been reported
previously.17 In this study, we conducted additional proteo-
mic data analysis focused on pro-survival pathways. Our
results indicate that these exosomes from human MSCs also
contain pro-survival-associated proteins from both the cAMP
response element-binding protein (CREB) pathway and shock
protein (HSP) pathways. Both of these pathways have been
previously shown to be affected by retinal ischemia, directly
and as a compensatory response of the retina to ischemia.30–35
Therefore, the prosurvival proteins elucidated in the present
study may help explain MSC exosomes ability to limit retinal
degradation induced by the OIR model. Based on these find-
ings, exosomes from human MSCs may have multiple
mechanisms of actions for their observed protective effect
on retinal ischemia. Numerous angiogenesis and survival
pathways in retinal issue may be enhanced by MSC exosome
treatment.
The current study explored a new route of exosome
administration for retinal ischemia treatment via intravitreal
injection. We demonstrated that this route of exosome
administration was well tolerated during the two-week dura-
tion of this study. The therapy was effective without concur-
rent use of systemic immunosuppression although the
exosomes were derived from human cells and used in mouse
eyes, and no ocular inflammation was detected. Furthermore,
our study showed that exosomes derived from human MSCs
cultured under hypoxic, serum-free conditions were effective
in reducing the severity of retinal ischemia in mice with OIR.
Our findings parallel a recent report by Mead and Tomarev
who showed that intravitreal injection of exosomes from
hMSCs resulted in preservation of ganglion cells in a model
of optic nerve injury.36 They noted that the content of the
exosomes was localized in the inner retina, the target tissue. In
this study of optic nerve injury by Mead and Tomarev, intra-
vitreal injection of exosomes from fibroblasts was used as a
control since the investigators noted no effect of exosomes
from fibroblasts on ganglion cell degeneration. In our study,
saline was injected in control eyes since exosomes from other
cells may contain factors that potentially affect retinal ische-
mia and neovascularization.
Intravitreal administration of MSCs has been shown to
have a protective effect in animal models of retinal ische-
mia-reperfusion injury. The effect could be simulated with
conditioned media.18,37 Since there are some safety concerns
about intravitreal administration of MSCs or conditioned
media, the use of exosomes isolated from conditioned media
is a potential safe alternative to cell therapy. Since exosomes
derived from MSCs have demonstrated efficacy in non-ocular
models of tissue ischemia,9–16 it is reasonable to hypothesize
that exosomes from MSCs will have a similarly positive effect
on retinal ischemia. Our study results support this hypothesis.
In summary, our study findings show that intravitreal
injection of exosomes from human MSCs is well-tolerated
and can have a protective therapeutic effect on retinal ische-
mia. No immunogenicity was detected despite the fact that
exosomes from human cells were administered to immuno-
competent mice. Intravitreal injection of exosomes from stem
cells may be a novel non-cellular approach to achieve efficacy
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and benefits of stem cell therapy without exposing the reci-
pient to potential safety concerns associated with cell therapy,
such as cellular proliferation or immune rejection. Further
studies will need to be performed to determine whether the
beneficial effect of these exosomes can be observed in other
models of retinal disease. Additional long-term safety infor-
mation and dose-response assessments are needed before this
therapy can be translated to clinical applications. Exosomes
derived from human MSCs can be used in an allogeneic
manner, since they are immune privileged. In addition, exo-
somes may hold other advantages beyond the use of MSCs for
clinical applications as exosomes may provide a more con-
centrated source of tissue healing factors with off-the-shelf
delivery capabilities. This is a very appealing novel non-cel-
lular therapeutic approach that warrants further exploration
in ophthalmology.
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